The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease• The Oral Delivery Challenge: Why It Requires More Than the Right Route• Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats•

Tag: Regulatory

Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease
Regulatory & Policy

Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease

OCT 30, 2026
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development
Clinical & Manufacturing

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development

OCT 16, 2026
New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia
Clinical & Manufacturing

New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia

SEP 24, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Clinical & Manufacturing

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

SEP 18, 2026
Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
Finance

Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health

SEP 16, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Infectious Disease & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

SEP 15, 2026